REFRACTORY GRADE 1 FOLLICULAR LYMPHOMA
Clinical trials for REFRACTORY GRADE 1 FOLLICULAR LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY GRADE 1 FOLLICULAR LYMPHOMA trials appear
Sign up with your email to follow new studies for REFRACTORY GRADE 1 FOLLICULAR LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental drug targets Hard-to-Treat lymphoma
Disease control OngoingThis early-stage trial tests a new drug called MEDI-570 in people with certain types of T-cell lymphoma that have come back or not responded to treatment. The main goals are to find the best dose and check for side effects. The drug works by helping the immune system attack cance…
Matched conditions: REFRACTORY GRADE 1 FOLLICULAR LYMPHOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
New drug duo aims to tame stubborn blood cancer
Disease control TerminatedThis study is testing whether a combination of two drugs, epcoritamab and tazemetostat, is safe and effective for adults with follicular lymphoma that has come back or not responded to prior therapy. The drugs work together to help the immune system attack cancer cells and block …
Matched conditions: REFRACTORY GRADE 1 FOLLICULAR LYMPHOMA
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Apr 20, 2026 16:18 UTC